The α_v integrin antagonists as novel anticancer agents: an update

Bibliography

• RUOSLAHTI E, PIERSCHBACHER M: Arg-Gly-Asp: A versatile cell recognition sequence. Cell (1986) 44:517–518.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• COX D, AOKI T, SEKI J, MOTOYAMA Y, YOSHIDA K: The pharmacology of the integrins. Med. Res. Rev (1994) 14:195–228.
   PubMed Web of Science ®Google Scholar
• ALBELDA SM, BUCK CA: Integrins and other cell adhesion molecules. FASEB (1990) 4:2868–2880.
   PubMed Web of Science ®Google Scholar
• CHERESH D: Integrins: structure, function and biological properties. Adv. Ma Cell Biol. (1993) 6:225–252.
   Google Scholar
• SEFTOR EB, SEFTOR EA, HENDRIX MJC: Molecular role (s) for integrins in human melanoma invasion. Cancer Metastasis Rev (1999) 18:359–375.
   PubMed Web of Science ®Google Scholar
• KOISTINEN P, HEINO J: Integrins in cancer cell invasion. In: Cell Invasion. Heino J, Kahari V-M (Eds.), Eurekah.com, Landes Bioscience, TX, USA (2002):1–27.
   Google Scholar
• GUADAGNO TM, OHTSUBO M, ROBERTS JM et al: A link between cyclin A expression and adhesion dependent cell cycle proliferation. Science (1993) 262:1592–1575.
   Web of Science ®Google Scholar
• JULIANO R, HASKILL S: Signal transduction from the extracellular matrix. J. Cell Biol. (1993) 120:577–585.
   PubMed Web of Science ®Google Scholar
• KORNBERG LJ, EARP HS, TURNER CE et al.: Signal transduction by integrins: Increased protein tyrosine phosphorylation caused by clustering of 13 integrins. Proc. Natl. Acad. Sci. USA (1991) 88:8392–8395.
   PubMed Web of Science ®Google Scholar
• KORNBERG LJ, EARP HS, PARSONS JT et al.: Cell adhesion or integrin clustering increased phorphorylation of a focal adhesion associated kinase. J. Biol. Chem. (1992) 117:1101–1107.
   Google Scholar
• GUAN JL, SHALLOWAY D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature (1992) 358:690–692.
   PubMed Web of Science ®Google Scholar
• GIANCOTTI FG, RUOSLAHTI E: Integrin signaling. Science (1999) 285:1028–1032.
   PubMed Web of Science ®Google Scholar
• •Discussion of integrin signalling and the regulation of activities governed by them.
   Google Scholar
• CALDERWOOD DA, HUTTENLOCHER A, KIOSSES WB et al.: Increased filamin binding to 13-integrin cytoplasmic domains inhibits cell migration. Nat. Cell Biol. (2001) 3:1060–1068.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: Bidirectional, allosteric signaling machines. Cell (2002) 110:673–687.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive discussion of howintegrins transmit information.
   Google Scholar
• PRICE JT, THOMPSON EW: Mechanism of tumour invasion and metastases: emerging targets for therapy. Expert Opin. Ther. Targets (2002) 6:217–233.
   PubMedGoogle Scholar
• ZETTER BR: Angiogenesis and tumor metastasis. Ann. Rev Med. (1998) 49:407–424.
   PubMed Web of Science ®Google Scholar
• KEELY P, PARISE L, JULIANO R: Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol. (1998) 8:101–106.
   PubMed Web of Science ®Google Scholar
• FRISCH SM, RUOSLAHTI E: Integrins and anoikis. Curr. Opin. Cell Biol. (1997) 9:701–706.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E, ENGVALL E: Integrins and vascular extracellular matrix assembly. Gin. Invest. (1997) 99:1149–1152.
   PubMed Web of Science ®Google Scholar
• BROOKS PC: Role of integrins in angiogenesis. Ear: J. Cancer (1996) 32A:2423–2439.
   PubMed Web of Science ®Google Scholar
• •An early review on this topic.
   Google Scholar
• XIONG JP, STEHLE T, DIEFENBACK B et al.: Crystal structure of the extracellular segment of integrin integrin a43. Science (2001) 294:339–345.
   PubMed Web of Science ®Google Scholar
• XIONG JP, STEHLE T, ZHANG R et al.: Crystal structure of the extracellular segment of integrin av33 in complex with an arg-gly-asp ligand. Science (2002) 296:151–155.
   PubMed Web of Science ®Google Scholar
• •The crystal structure of the extracellular segment of 03 shown in a complex with a cyclic peptide containing an RGD sequence. This ligand binding induces small changes in the ctv component compared with the N.
   Google Scholar
• CHERESH DA: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. USA (1987) 84:6471–6475.
   PubMed Web of Science ®Google Scholar
• LEAVESLEY DI, FERGUSON GD, WAYNER EA et al: Requirement of integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J. Cell Biol. (1992) 117:1101–1107.
   PubMed Web of Science ®Google Scholar
• WICKHAM TJ, MATHIAS P, CHERESH DA, NEMEROW GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 73:309–319.
   PubMed Web of Science ®Google Scholar
• ELICEIRI BP, CHERESH DA: Role of alpha v integrins during angiogenesis. Cancer (2000) 6:S245–S249.
   Web of Science ®Google Scholar
• MORETTI S, MARTINI L, BERTI E, PINZI C, GIANNOTTI B: Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res. (1993) 3:235–239.
   PubMed Web of Science ®Google Scholar
• SCHADENDORF D, GAWLIK C, HANEY U, OSTMEIER H, SUTER L, CZARNETZKI B: Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocytic tumors. Pathol (1993) 170:429–434.
   Web of Science ®Google Scholar
• DANEN EH, JANSEN KF, VAN KRAATS AA, CORNELISSEN IM, RAITER DJ, VAN MUIJEN GN: Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int. J. Cancer(1995) 61:491–496.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, MUELLER BM, ROMERDAHL CA, CHERESH DA: Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. Clin. Invest. (1992) 89:2018–2022.
   Google Scholar
• SANDERS LC, FEUDING-HABERMANN B, MUELLER BM, CHERESH DA: Role of alpha v integrins and vitronectin in human melanoma cell growth. Cold Spring Harb. Symp. Quant. Biol. LVH(1992) 57:233–240.
   PubMedGoogle Scholar
• GLADSON CL, CHERESH DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. Gin. Invest. (1991) 88:1924–1932.
   Google Scholar
• GLADSON CL: Expression of alpha v beta3 in small blood vessels of glioblastoma tumors. J. Neuropathol Exp. Neurol (1996) 55:1143–1149.
   PubMed Web of Science ®Google Scholar
• LIAPIS H, ADLER LM, WICK MR, RADER JS: Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Human Path. (1997) 28:443–449.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, MUELLER BM, ROMERDAHL CA, CHERESH DA: Involvement of integrin alpha v gene expression in human melanoma tumorigenicity. Clin. Invest. (1992) 89:2018–2022.
   Google Scholar
• PETITCLERC E, STROMBLAD S, VON SCHALSCHA TL et al.: Integrin alpha (v) beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. (1999) 59:2724–2730.
   Google Scholar
• SEFTOR RE, SEFTOR EA, GEHLSEN KR et al.: Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA (1992) 89:1557–1561.
   PubMed Web of Science ®Google Scholar
• NIP J, SHIBATA H, LOSKUTOFF D, CHERESH DA, BRODT P: Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin. I Clin. Invest. (1992) 90:1406–1413.
   PubMed Web of Science ®Google Scholar
• ALBELDA SM, METTE SA, ELDER DE et al.: Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. (1990) 50:6757–6764.
   PubMed Web of Science ®Google Scholar
• HIEKEN TJ, FAROLAN M, RONAN SG et al.: Beta 3 integrin expression in melanoma predicts subsequent metastasis. &lig. Res. (1996) 63:169–173.
   Google Scholar
• GASPARINI G, BROOKS PC, BIGANZOLI E et al.: Vascular integrin alpha v beta 3: A new prognostic indicator in breast cancer. Clin. Cancer Res. (1998) 4:2625–2634.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY AMP, REISFELD RA, CHERESH DA: Integrin alpha v beta 3 rescues melanoma cells from apoptosis in a three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA (1994) 91:8856–8860.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, O'TOOLE TE, SMITH JW et al.: Integrin activation controls metastasis in human breast cancer. Proc. Nati Acad. Sci. USA (2001) 98:1853–1858.
   PubMed Web of Science ®Google Scholar
• •Discussion of the role of activated and non-activated 03 in breast cancer and how inhibition may affect the disease outcome.
   Google Scholar
• FILARDO EJ, BROOKS PC, DEMING SL, DAMSKY C, CHERESH DA: Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo.j Cell Biol. (1995) 130:441–450.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug to tumor vasculature in a mouse model. Science (1998) 279:377–380.
   PubMed Web of Science ®Google Scholar
• DeNARDO SJ, BURKE PA, LEIGH BR et al.: Neovascular targeting with cyclic RGD peptide (eRGDI-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother. Radiopliann. (2000) 15:71–79.
   PubMed Web of Science ®Google Scholar
• •Discussion of the aj33 receptor as a target to increase permeability of tumour vessels as a strategy to increase tumour vascular permeability.
   Google Scholar
• MARSHALL JF, RUTHERFORD DC, HAPPERFIELD L et al: Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br. Cancer (1998) 77:522–529.
   Google Scholar
• ARAP W, KOLONIN MG, TREPEL M et al.: Steps toward mapping the human vasculature by phage display. Nat. Med. (2002) 8:121–127.
   PubMed Web of Science ®Google Scholar
• ••Peptides that home to specific vascularbeds are identified. The data represent a step in the construction of a molecular map of human vasculature.
   Google Scholar
• ANDERSON SA, RADER RK, WESTLIN WF et al.: Magnetic resonance contrast enhancement of neovasculature with alpha v beta 3-targeted nanoparticles. Magn. Reson. Med. (2000) 44:433–439.
   PubMed Web of Science ®Google Scholar
• HAUBNER R, WESTER HJ, REUNING U et al.: Radiolabeled alpha v beta 3 integrin antagonists: A new class of tracers for tumor targeting. Nucl. Med. (1999) 40:1061–1071.
   Web of Science ®Google Scholar
• ••Description of the first radiolabelledantagonist.
   Google Scholar
• ARAP W, HAEDICKE W, BERNASCONI M et al.: Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. USA (2002) 99:1527–1531.
   PubMed Web of Science ®Google Scholar
• •A homing chimeric peptide delayed the development of cancer in cancer-prone mice.
   Google Scholar
• SIVOLAPENKO GB, SKARLOS D, PECTASIDES D et al.: Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing syntheic peptide. Ear. Nucl. Med. (1998) 25:1383–1389.
   PubMedGoogle Scholar
• SIPKINS DA, CHERESH DA, KAZEMI MR, NEVIN LM, BEDNARSKI MD, LI KC: Detection of tumor angiogenesis in vivo by alpha v beta 3-targeted magnetic resonance imaging. Nat. Med. (1998) 4:623–626.
   PubMed Web of Science ®Google Scholar
• POSEY JA, KHAZAELI MB, DELGROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitonectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother. Radiopliann. (2001) 16:125–132.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, THEESFELD CL, SUGITA M et al.: Involvement of integrin alpha v beta 3 and alpha v beta Sin ocular neovascualar diseases. Proc. Natl. Acad. Sci. USA (1996) 93:9764–9769.
   PubMed Web of Science ®Google Scholar
• PREISSNER KT, KANSE HP, HAMMES HP: Integrin chatter and vascular function in diabetic retinopathy. Horin. Metab. Res. (1997) 29:643–645.
   PubMed Web of Science ®Google Scholar
• ELICEIRI BP, KLEMKE R, STROMBLAD S, CHERESH D: Integrin av33 requirement for sustained mitogen-activated protein kinase activated protein kinase activity during angiogenesis. Cell Biol. (1999) 14:1255–1263.
   Google Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW et al.: Definition of two angiogenic pathways by distinct av integrins Science (1995) 27:1500–1502.
   Google Scholar
• •Discussion of distinct angiogenic pathways for a.,133 and a5.
   Google Scholar
• ELICEIRI BP, CHERESH D: The role of alpha v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J. Clin. Invest. (1999) 103:1227–1230.
   PubMed Web of Science ®Google Scholar
• LUNA J, TOBE T, MOUSA S et al: Antagonists of integrin av33 inhibit retinal neovascularization in a murine model. Lab. Invest. (1996) 75:563–573.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RAF, CHERESH DA: Requirement of vascular integrin av33 for angiogenesis. Science (1994) 264:569–571.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R et al.: Anti-integrin al/133 blocks human breast cancer growth and angiogenesis in human skin. Clin. Invest. (1995) 96:1815–1822.
   Google Scholar
• KERR JS, WEXLER RS, MOUSA SA et al.: Novel small molecule av integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res. (1999) 19:959–968.
   PubMed Web of Science ®Google Scholar
• KUMAR CC, MALKOWSKI M, YIN Z et al.: Inhibition of angiogenesis and tumor growth by SCH221153, a dual av33 and avP5integrin receptor antagonist. Cancer Res. (2001) 61:2232–2238.
   PubMed Web of Science ®Google Scholar
• REYNOLDS LE, WYDER L, LIVLEY JC et al.: Enhance pathological angiogenesis in mice lacking 33 integrin or 33 and 35 integrins. Nat. Med. (2002) 8:27–34.
   PubMed Web of Science ®Google Scholar
• CHERESH D, STUPACK DG: Integrin- mediated death: An explanation of the integrin knockout phenotype?Nat. Med. (2002) 8:193–194.
   Web of Science ®Google Scholar
• HYNES RO: A reevaluation of integrins as regulators of angiogenesis. Nat. Med. (2002) 8:918–921.
   PubMed Web of Science ®Google Scholar
• ••Discussion of integrins as negative regulators of angiogenesis and drugs targeting them as agonists not antagonists.
   Google Scholar
• PITTS WJ, WITYAK J, SMALLHEERJM et al.: Isoxazolines as potent antagonists of the integrin alpha v beta 3.j Med. Chem. (2000) 43:27–40.
   Google Scholar
• BATT DG, PETRAITIS JJ, HOUGHTON GC et al.: Disubstituted indazoles as potent antagonists of the integrin alpha v beta 3.j Med. Chem. (2000) 43:41–58.
   Google Scholar
• MILLER WH, ALBERTS DP, BHATNAGAR PK et al.: Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine gly-asp mimetic.' Med. Chem. (2000) 43:22–26.
   Google Scholar
• ALLMAN R, COWBURN P, MASON M: In vitro and in vivo effects of a cyclic peptide with affinity for the alpha v beta 3 integrin in human melanoma cells. Eur. Cancer (2000) 36:410–422.
   PubMed Web of Science ®Google Scholar
• MAESHIMA Y, YERRAMALLA UL, DHANABAL M et al: Extracellular matrix-derived peptide binds to avI33integrin and inhibits angiogenesis. Biol. Chem. (2001) 276:31959–31968.
   Web of Science ®Google Scholar
• HOEKSTRA WJ, POULTER BL: Combinatorial chemistry techniques applied to nonpeptide integrin antagonists. Carr. Med. Chem. (1998) 5:195–204.
   PubMed Web of Science ®Google Scholar
• PASCO S, HAN J, GILLERY P et al.: A specific sequence of the non-collagenous domain of the av(IV) chain of Type IV collagen inhibits expression and activation of matrix metalloproteinases by tumor cells. Cancer Res. (2000) 60:467–473.
   PubMed Web of Science ®Google Scholar
• CORBETT JW, GRACIANI NR, MOUSA SA, DEGRADO WF: Solid phase synthesis of a selective a433 integrin antagonist library. Bioorg. Med. Chem. Lett. (1997) 40:2289–2292.
   Google Scholar
• DUGGAN DE, HUTCHINSON JH: Ligands to the integrin receptor alpha v beta 3. Expert Opin. Ther. Patents (2000) 10:1367–1383.
   Web of Science ®Google Scholar
• MILLER WH, KEENAN PM, WILLETTE RN, LARK MW: Identification and in vivo efficacy of small-molecule antagonists of integrin alpha v beta 3 (the vitronectin receptor). Drug Discov. Today (2000) 5:397–408.
   PubMed Web of Science ®Google Scholar
• ALBINI A, NOONAN D, SANTI L: Angiogenesis at the interface between basic and clinical research. Intern.' Biol. Markers (1999) 14:202-206. ao.MEDIMMUNE. MedImmune initiates phaseI/II clinical study with Vitaxin. Expert Rev. Anticancer Ther. (2001) 1:166.
   Google Scholar
• PATEL SR JENKINS J, PAPADOPOLOUS N et al.: Pilot study of Vitaxin- an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 92:1347-1348. Patents
   Google Scholar
• DUPONT PHARMACEUTICALS: U56214834 (2001). on. MERCK & Co.: U56211184 (2001).
   Google Scholar